Device Trial Radar · NCT05329129
OssDsign® Spine Registry Study ("Propel")
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Mar 23, 2022
Primary completion
Mar 23, 2030
Study completion Apr 1, 2030
Sponsor
- Lead sponsor
- OssDsignNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 14, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
Summary
As written by the sponsor on the registry.
The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.
Conditions
- Degenerative Disc Disease
- Spinal Stenosis
Interventions
OssDsign® CatalystDevice
An osteoconductive, resorbable, porous, 100 % nano synthetic calcium phosphate bone void filler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of bone fusionTime frame: 12 months ± 60 days post-operative examination
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Community Health Partners Neuroscience
Fresno, California · Recruiting
Memorial Orthopaedic Surgical Group
Long Beach, California · Recruiting
San Diego Neurosurgery
San Diego, California · Terminated
13 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.